Eywa

Eywa Biotech is pioneering the biomanufacturing of next-generation psychedelic compounds — such as psilocybin and DMT — through synthetic biology and AI-driven strain engineering, creating scalable, pharmaceutical-grade molecules to power a new era of mental health treatments. The company's mission is to make psychedelic-assisted therapy safe, accessible and affordable by building the world's first sustainable supply chain for active psychedelic ingredients.

With 1 in 4 people affected by mental illness and over 700,000 suicides annually, the urgency and scale of the market are unprecedented. The global mental health industry exceeds $430B, with a serviceable market for psychedelic therapies estimated at $50B and growing rapidly across North America, Europe and Latin America.

The team combines deep biotech, neuroscience and entrepreneurship expertise. CEO and co-founder Victoria Costa Paz leads the company's strategic and operational growth, recently completing the Draper University Hero Program. COO Pablo Salavarría, former executive at Stämm, brings extensive experience scaling bioengineering operations, while Technical Lead Jorge Wenzel, a PhD in Chemistry and Biotechnology, heads R&D and CRISPR-based molecule production.